BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24635704)

  • 1. Personalized therapy for breast cancer.
    De Abreu FB; Schwartz GN; Wells WA; Tsongalis GJ
    Clin Genet; 2014 Jul; 86(1):62-7. PubMed ID: 24635704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine.
    De Abreu FB; Wells WA; Tsongalis GJ
    Am J Pathol; 2013 Oct; 183(4):1075-1083. PubMed ID: 23920325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].
    Gonçalves A; Moretta J; Eisinger F; Bertucci F
    Bull Cancer; 2013 Dec; 100(12):1295-310. PubMed ID: 24225763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized medicine: present and future of breast cancer management.
    Sabatier R; Gonçalves A; Bertucci F
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer management: opportunities and barriers to an individualized approach.
    Perez EA
    Oncologist; 2011; 16 Suppl 1():20-2. PubMed ID: 21278437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care.
    Roukos DH
    Expert Rev Mol Diagn; 2010 Jan; 10(1):33-48. PubMed ID: 20014921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.
    Fuqua SA; Cui Y
    Breast Cancer Res Treat; 2004; 87 Suppl 1():S3-10. PubMed ID: 15597215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics of adjuvant therapy for breast cancer.
    Kim SR; Paik S
    Cancer J; 2011; 17(6):500-4. PubMed ID: 22157294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy.
    Baehner FL; Lee M; Demeure MJ; Bussey KJ; Kiefer JA; Barrett MT
    J Surg Oncol; 2011 May; 103(6):563-73. PubMed ID: 21480251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theranostic and molecular classification of breast cancer.
    Cornejo KM; Kandil D; Khan A; Cosar EF
    Arch Pathol Lab Med; 2014 Jan; 138(1):44-56. PubMed ID: 24377811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine: the road ahead.
    Mehta R; Jain RK; Badve S
    Clin Breast Cancer; 2011 Mar; 11(1):20-6. PubMed ID: 21421518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer gene expression profiling: clinical trial and practice implications.
    Loi S; Desmedt C; Cardoso F; Piccart M; Sotiriou C
    Pharmacogenomics; 2005 Jan; 6(1):49-58. PubMed ID: 15723605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized therapy for breast cancer: a dream or a reality?
    Zardavas D; Pugliano L; Piccart M
    Future Oncol; 2013 Aug; 9(8):1105-19. PubMed ID: 23902243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative biomarker development for personalized medicine in breast cancer care.
    Zografos GC; Roukos DH
    Biomark Med; 2011 Feb; 5(1):73-8. PubMed ID: 21319967
    [No Abstract]   [Full Text] [Related]  

  • 20. Individualized targeted therapy for glioblastoma: fact or fiction?
    Weller M; Stupp R; Hegi M; Wick W
    Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.